Polly – Interview 09
Polly was invited to be in a trial comparing tamoxifen against a placebo for breast cancer in the 1990s. She decided not to take part, because she felt there was already good evidence to support the use of tamoxifen.
Polly discovered she had early-stage breast cancer in the 1990s after her sister was diagnosed with breast cancer and other family members were called in to be screened. She had a lumpectomy, and was then asked to take part in a trial comparing the drug tamoxifen with a placebo or sugar pill;. In principle, Polly feels it is important for people to take part in research, and is in favour of well-designed clinical trials as the best way to advance medical knowledge. However, she already knew quite a bit about tamoxifen, partly because of family history and partly through her work as a journalist. She had heard of a trial which had already been conducted in the United States. She understood this had shown that taking tamoxifen gave you a 30% better chance of survival. She also knew that tamoxifen was already being prescribed outside the trial to other women at the same hospital.
Polly therefore had doubts about the value of this particular trial. She discussed it with medical friends and with the doctor running the trial, who said that although there was some evidence, they needed more studies to be sure, and more evidence from the UK. Polly was not convinced that the extra knowledge that might be gained was worth the risk to her of being randomised to the group not receiving tamoxifen. She therefore decided not to take part, and was prescribed tamoxifen anyway. She took it for five years, and had some initial side effects of menopausal symptoms. She tried hormone replacement therapy (HRT) to help with this, but found it made her gain weight, so she stopped taking the HRT.
She still feels it is important for people to take part in clinical trials unless they have good reason not to, but advises people to seek out as much evidence-based information as possible and ask as many questions as they need to. She feels health professionals running trials should ask themselves whether they;d be happy for one of their family members to be randomised before they ask this of their patients.